Vetr Inc. disclosed Allergan plc Ordinary Shares (NYSE:AGN), boosting its stock price target to $288.87 earlier today
- Updated: September 17, 2016
Allergan plc Ordinary Shares (NYSE:AGN) had its target price increased to $289 by Vetr Inc. in an issued report released 8/22/2016. The new target price suggests a potential upside of 0.14% from the bussiness’ last closing price.
On 8/19/2016, Mizuho Securities reported about Allergan plc Ordinary Shares(NYSE:AGN) raised the target price from $248.00 to $318.00 that indicated a possible upside of 0.26%.
Yesterday Allergan plc Ordinary Shares (NYSE:AGN) traded 0.51% lower at $253.54. AGN’s 50-day average is $247.03 and its two hundred day average is $244.75. The last stock price is up 0.18% relative to the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. Trading volume was was up over the average, with 3,358,894 shares of AGN changing hands over the typical 3,000,800 shares..
See Graphic Below:
Allergan plc Ordinary Shares has a price-earnings of 23 with a 52 week low of $195.50 and a 52 week high of $322.68 and has a total market value of $0.0.
A total of 16 equity analysts have reported on the company. Seven analysts rate the company a strong buy, 11 firms rate the stock a buy, two firms rate the stock a hold, 0 rate the company to underperform, and finally 0 brokeragesrate the stock as sell with an average target stock price of $293.75
General Information About Allergan plc Ordinary Shares (NYSE:AGN)
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physiciansÂ’ offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, and Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.